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BRAF V600E is the most common driver mutation in human cutaneous melanoma and is 
frequently accompanied by loss of the tumor suppressing phosphatase PTEN. Recent 
evidence suggests a co-operative role for RAC1 activity in BRAF V600E -driven melanoma 
progression and drug resistance. However, the underlying molecular mechanisms and the role 
of RAC1 downstream targets are not well explored. Here, we examine the role of the 
NCKAP1 subunit of the pentameric cytoskeletal SCAR/WAVE complex, a major 
downstream target of RAC1, in a mouse model of melanoma driven by BRAF V600E; PTEN 
loss. The SCAR/WAVE complex is the major driver of lamellipodia formation and cell 
migration downstream of RAC1 and depends on NCKAP1 for its integrity. Targeted deletion 
of Nckap1 in the melanocyte lineage delayed tumor onset and progression of a mutant Braf ; 
Pten loss driven melanoma mouse model. Nckap1 depleted tumors displayed fibrotic stroma 
with increased collagen deposition concomitant with en anced immune infiltration. Nckap1 
loss slowed proliferation and tumor growth, highligting a role in cell cycle progression. 
Altogether, we propose that NCKAP1-orchestrated actin polymerization is essential for tumor 
progression and maintenance of tumor tissue integrity in a mutant Braf ; Pten loss driven 












Metastatic cutaneous melanoma remains a major health problem, even though insights into 
the genetic drivers have increased therapeutic options (Merlino et al., 2016). BRAF is a 
serine/threonine kinase acting mainly through the MAPK pathway. Activating mutations in 
the BRAF gene, including BRAF V600E, are major drivers of cutaneous melanoma and targeted 
therapies, such as vermurafenib, have allowed suppression of oncogenic signalling, improving 
therapeutic outcomes. In addition, immunotherapies, such as anti-PD1 or anti-CTLA-4 
monoclonal antibodies can reprogramme the immune system against tumors. These 
advancements have in some cases have resulted in major survival improvements for 
metastatic melanoma (reviewed in Gellrich et al., 2020). However, tumor heterogeneity and 
emergence of resistance during treatment imposes a need for better understanding the 
underlying mechanisms of cutaneous melanoma progression (Gellrich et al., 2020). 
Preclinical mouse models mimic common human oncogene/tumor suppressor combinations 
and recapitulate disease progression (Perez-Guijarro et al., 2017). In mice, expression of 
BRAFV600E from the endogenous locus, in the melanocytic lineage using Tyrosinase promoter 
driven Cre (Tyr::Cre), drives naevi formation and dermal expansion of melanocytes (Dhomen 
et al., 2009). Combination with deletion of the tumor suppressor Pten, a genetic event that co-
occurs with BRAFV600E in a significant proportion of human melanomas, led to aggressive 
disease in mice (Dankort et al., 2009). 
 
RAC1 mutations occur in 8-10% of sun-exposed melanomas, ost commonly a proline to 
serine P29S mutation (Halaban, 2015). RAC1 encodes for a small GTPase which is a major 
regulator of actin cytoskeleton dynamics and RAC1P29S is a more active variant (reviewed in 









cell surface expression of PD1 (Watson et al., 2014).  RAC1P29S expression in a mouse model 
can drive transcriptional reprogramming via the actin-responsive serum response factor SRF 
or the RAC1-binding kinase PAK (Lionarons et al., 2019). However, the involvement of the 
SCAR/WAVE complex, a major cytoskeletal effector of RAC1 activity, has not been 
explored in melanoma. The SCAR/WAVE complex consists of five subunits: NCKAP1, 
CYFIP1, ABI1, SCAR/WAVE, HSPC300 and their isoforms (Pollitt and Insall, 2009). The 
different subunits function together, with CYFIP1 and NCKAP1 being core subunits (Ibarra 
et al., 2006, Steffen et al., 2004, Tang et al., 2013). The SCAR/WAVE complex drives 
remodelling of the actin cytoskeleton in response to activation of RAC1, promoting cell 
migration and uptake of nutrients from the microenvironment via macropinocytosis or 
phagocytosis (Stradal et al., 2004) (Steffen et al., 2004). 
 
Regardless of the RAC1 mutational status, loss of PTEN enhances PI-3-kinase signaling, 
leading to a positive feedback loop for activation of RAC1 (Chalhoub and Baker, 2009). The 
SCAR/WAVE complex is a well-established direct target of RAC1 activation (Chen et al., 
2017). We deleted the gene coding for the NCKAP1 subunit in BRAFV600E/PTEN loss-driven 
melanomas in mice and found that loss of Nckap1 significantly reduced tumor burden and 
slowed tumour growth. NCKAP1 deletion led to altered signalling, increased tumor fibrosis 
and enhanced infiltration by several immune cell types. Taken together, our data suggest an 
important role of the SCAR/WAVE complex in melanoma progression driven by BRAFV600E 














RAC1 plays an essential role in Tyr::NrasQ61K driven melanoma and melanocytic dermal 
expansion (Li et al., 2012). However, the role of RAC1 downstream effectors such as the 
SCAR/WAVE complex are largely unknown. Therefore, we generated a mouse model with 
conditional deletion of Nckap1 (Figure S1a, Methods). We crossed Nckap1f/f conditional 
mice with an established malignant melanoma mouse model, 
Tyr::CreERT2+;BrafV600E+;Ptenwt/f (Dankort et al., 2009, Dhomen et al., 2009, Suzuki et al., 
2001), to assess the role of NCKAP1 in melanoma progression (Figure S1b). 
 
Mice carrying the genotype Tyr::CreERT2+;BrafV600E+;Ptenwt/f;Nckap1wt/wt and 
Tyr::CreERT2+;BrafV600E+;Ptenwt/f;Nckap1f/f , hereafter referred as Nckap1wt/wt and Nckap1f/f 
mice, were induced by skin painting (Methods and Table S1), leading to BrafV600E expression 
together with loss of Pten (heterozygous) and Nckap1 (homozygous) alleles in the 
melanocytic lineage (Figure S1b-d). Nckap1wt/wt mice developed primary melanoma with 
expected penetrance and latency to previous observations (Dankort et al., 2009) and therefore 
were used as littermate controls. Both Nckap1f/f and Nckap1wt/wt mice developed naevi (e.g. 
clusters of pigmented dermal melanocytes) and tumors (e.g. larger clusters both pigmented 
and unpigmented and penetrated deeper into the dermis) (Figure 1a-b), which were allowed 
to grow until the largest reached 1.2 cm in diameter. The number of tumors in Nckap1f/f mice 
(average 1.71±0.25 tumors/mouse: n=16 mice; p<0.0001) was reduced ompared to 
Nckap1wt/wt mice (average 6.75±0.9 tumors/mouse: n=14 mice) (Figure 1c). Tumor burden at 
endpoint was also reduced in Nckap1f/f (n=16 mice; 662.6±84.4 mm3; p<0.01) compared to 
Nckap1wt/wt mice (n=14 mice; 1260±133 mm3) (Figure 1d). Tumors from Nckap1wt/wt and 
Nckap1f/f mice displayed similar morphology (Figure 1e-f). Thus, Nckap1 is important for 









Loss of Nckap1 delayed tumor growth 
 
Since the tumours showed delayed growth in the absence of NCKAP1, we examined the 
tumour growth kinetics. Nckap1f/f tumors (mean±SEM; 2.34±0.7, n=5 mice) showed a 
significantly (P<0.05) lower percentage of BrdU positive nuclei per mm2 compared to 
Nckap1wt/wt tumors (mean±SEM; 5.18±0.7, n=5 mice) (Figure 2a-b). This was not likely due 
to a failure to enter the cell cycle, as the %Ki67 positive nuclei per mm2 in Nckap1f/f 
(mean±SEM; 25.18±1.78: n=7 mice) was similar to Nckap1wt/wt (mean±SEM; 26.71±2.74, 
n=5 mice) tumors (Figure 2c-d). However, there was a significant reduction (P <0.01) in 
cyclin D1 positive nuclei/mm2 in Nckap1f/f (mean±SEM; 15.02 ±3.23, n=8 mice) compared 
with Nckap1wt/wt (mean±SEM; 38.95 ± 6.00, n=8 mice) (Figure 2e-f), indicating a delay in G1 
cell cycle progression. The average size of Nckap1wt/wt and Nckap1f/f tumors from the day of 
first appearance was also reduced in Nckap1f/f (Figure 2g and Table S2). Tumors from 
Nckap1f/f (n=7 mice) expanded more slowly compared to Nckap1wt/wt (n=7 mice). Average 
tumor size in Nckap1f/f mice was 46.75 ± 9.18 mm3 which is significantly smaller than the 
average tumor size of 164.1 ± 15.04 mm3 (P< 0.0001) in Nckap1wt/wt at day 14; 62.07 ± 18.11 
mm3 in Nckap1f/f and 326.6 ± 45.55 mm3 (P< 0.001)in Nckap1wt/wt at day 21; 146.1 ± 30.08 
mm3 in Nckap1f/f and 569.5 ± 70.32 mm3 (P< 0.0001) in Nckap1wt/wt at day 28. Thus, loss of 
Nckap1 slowed cancer cell cycle progression and proliferation of melanomas, leading to 
fewer and smaller lesions at comparable time points. This phenotype is reminiscent of the role 
of RAC1 downstream of NRAS in NRasQ61K and loss of Ink4a-/- mouse melanoma model 
(Ackermann et al., 2005 and Li et al., 2012a), suggesting that the SCAR/WAVE complex 










Loss of Nckap1 delayed melanocyte dermal expansion, nevus appearance and tumor 
onset 
 
We next explored the various stages of melanoma progression and noticed a significant (P
<0.01) delay in the appearance of nevi in the back skin after tamoxifen induction in Nckap1f/f 
(Mean±SEM; 61.21±3.12 days; n=14 mice) compared to Nckap1wt/wt mice (Mean±SEM; 
43.87±2.75 days; n=15 mice) (Figure 3a). Nckap1f/f mice also showed delayed progression 
from naevus to tumor (Mean±SEM; 8.66±1.58; n=11 mice) compared to Nckap1 wt/wt 
(Mean±SEM; 32.67±6.85; n=15 mice) and tumor-free survival was extended by ~150% in 
Nckap1f/f compared to Nckap1wt/wt (median tumor-free survival from 52 to 78 days) (Figure 
3b and Figure S1e). It was previously observed that constitutive exprssion of mutant 
NRasQ61K in the melanocyte lineage led to RAC1-dependent pos natal dermal expansion of 
melanocytes (Li et al., 2012). Given that RAC1 activates Nckap1, we quantified dermal 
melanocyte clusters from Nckap1wt/wt and Nckap1f/f back skin in endpoint 1.2cm tumours (Fig 
3c-d). The percentage of pigmented area (melanocyte clusters)/mm2 was 14.59±2.07 
(mean±SEM) for Nckap1f/f (n=6 mice) which was significantly higher (P<0.05) than 
8.23±1.59 (mean±SEM) for Nckap1wt/wt (n=8 mice) (Figure 3e), indicating that dermal 
expansion of melanocytes still occurs in Nckap1 knoc outs, but that de-differentiation as 
demonstrated by Laurette (Laurette et al., 2020) may be affected by loss of Nckap1. The 
number of pERK (p42/44, extracellular related signal kinase) positive cells/mm2 was similar 
(P=0.38) between Nckap1f/f (mean±SEM; 8.00±1.85; n=6 mice) and Nckap1wt/wt tumors 
(mean±SEM; 11.88±4.02; n=5 mice) (Figure S2a-c) suggesting NCKAP1 is dispensable for 
ERK signaling downstream of BRafV600E. Due to the delay in tumor appearance and slow 
growth of tumors, the median survival time (endpoint = largest tumor is 1.2cm) of 








84.5 to 136 days) upon Nckap1 loss (Figure 3f) with (P<0.0001) by Log-rank (Mantel-cox) 
test. Altogether, Nckap1 is dispensable for dermal expansion, but plays an important role in 
naevus formation and progression to melanoma tumors. 
 
Nckap1 loss induces fibrosis in Braf V600E PTEN loss-driven melanoma. 
Extracellular matrix (ECM) drives tumor progression a d metastasis (Hynes, 2009, Lu et al., 
2012, Naba et al., 2016). Collagen is one of the major ECM proteins aiding tumor survival 
and growth (Lu et al., 2012) and high levels of collagens correlate with poor outcome in 
human melanomas (Miskolczi et al., 2018). Picrosiriu  red staining of tumours of identical 
endpoint size range showed a strong deposition of collagen in Nckap1f/f compared to 
Nckap1wt/wt tumors  (Figure 4a, b). Specifically, the percentage of picrosirius red positive 
areas/mm2 was significantly (P<0.05) increased in Nckap1f/f tumors (mean±SEM; 
57.66±9.08; n=6 mice) compared to Nckap1wt/wt tumors (mean±SEM; 32.87±5.64; n=7 mice) 
(Figure 4c and Figure S3a-d). Two-photon microscopy and second harmonic imaging of 
freshly prepared tumor sections (Rath et al., 2017) revealed the organisation (correlation) of 
the collagen to be similar (Figure 4d), however, Nckap1f/f tumors (n=11) contained 
substantially more collagen (homogeneity) than Nckap1wt/wt tumors (n=11) (Figure 4e). TGFβ 
signaling is important for ECM deposition and we observed that nuclear pSMAD3 
(downstream TGFβ target) was significantly (p <0.05) elevated in Nckap1f/f (n = 6) compared 
to control Nckap1wt/wt tumors (n = 5) potentially implicating TGFβ signalling in the fibrotic 
response (Figure S3e-g). Cancer associated fibroblasts (CAFs) are a major sou ce of collagen 
in the tumour microenvironment (Franco et al., 2010), but the total α-SMA (alpha smooth 
muscle actin, CAF marker) positive area was similar between Nckap1wt/wt and Nckap1f/f 
tumors (mean±SEM; 39.35±6.285 in Nckap1wt/wt n=8 mice; 42.28±6.04 in Nckap1f/f n=8 









Constitutive BRAFV600E expression induces senescence through accumulation of p21, 
p16INK4A, and p53 cell cycle blockers (Dhomen et al., 2009). Therefore, we queried whether 
Nckap1 loss could affect tumor senescence by quantifying p21 positive cells from Nckap1wt/wt 
and Nckap1f/f tumors (Figure S4a-b) but found no difference between Nckap1f/f tumors 
(mean±SEM; 42.70±5.14; n=8 mice) and Nckap1wt/wt tumors (mean±SEM; 49.71±2.14; n=11 
mice) (Figure S4a-c). So, while loss of Nckap1 enhances fibrosis, it does not drive excessive 
recruitment of α-SMA positive CAFs or obvious senescence. 
NCKAP1 engages ECM and links nutrient signals in Braf V600E PTEN loss-driven 
melanoma. 
We asked if the excessive fibrotic matrix in Nckap1f/f tumors might drive YAP transcriptional 
activation. Indeed, the percentage of YAP positive cells/mm2 was significantly increased 
(P<0.05) in Nckap1f/f tumors (mean±SEM; 20.18±3.66 ; n=6 mice) compared to Nckap1wt/wt 
tumors (mean±SEM; 7.54±1.62; n=6 mice) (Figure S5a-c). While the adhesion and 
oncogenic kinase Src was a candidate driver, the number of active Src (pSrc-Tyr416) positive 
cells/mm2 was significantly (P<0.01) lower in Nckap1f/f tumors (mean±SEM; 68.77±10.57, 
n=7 mice) compared to Nckap1wt/wt tumors (mean±SEM; 128.4±15.41, n=7 mice) (Figure 
S5d-f).  Thus, although nuclear YAP in melanomas can be driven by fibrosis associated with 
loss of Nckap1, this is not accompanied by increased phospho-Src and surprisingly is 
independent of actin dynamics downstream of the SCAR/WAVE complex. 
Mammalian Target of Rapamycin (mTOR) links nutrient availability to tumor growth and its 
activity depends on SCAR/WAVE complex-mediated signaling (Rainero et al., 2015). We 
therefore measured the activation status of mTOR using anti-phospho-S6 (Ribosomal Protein 
– Ser235/236), a well-known mTOR activity reporter. The percentage of pS6 positive 









n=8 mice) compared to Nckap1wt/wt tumors (mean±SEM; 46.90±6.08; n=8 mice) (Figure S6a-
c) indicating a link between NCKAP1 and nutrient sensing and growth in tumours. 
Nckap1 loss induces HIF1α expression and reduced vascularization in mutant Braf ; 
Pten loss-driven melanoma. 
 
Expression of hypoxia-inducible transcription factor (HIF1α) correlates with fibrosis and 
collagen deposition in cancers (Gilkes et al., 2014). We thus stained serial sections of 
Nckap1wt/wt and Nckap1f/f tumors for S100 (melanoma marker), HIF1α and CD31 
(vasculature) (Figure 5a-h). HIF1α expression was highly enriched in the stromal cells 
surrounding S100 positive areas in Nckap1f/f tumors compared to Nckap1wt/wt tumors (Figure 
5a,b,d,e). The percentage of HIF1α positive area/mm2 was significantly (P<0.01) higher in 
Nckap1f/f tumors (mean±SEM; 41.67±5.58; n=7 mice) compared to Nckap1wt/wt tumors 
(mean±SEM; 16.82±4.89; n=7 mice) (Figure 5g). In addition, the percentage of CD31 
positive area/mm2 was significantly (P<0.001) lower in Nckap1f/f tumors (mean±SEM; 
1.54±0.15; n=9 mice) compared to Nckap1wt/wt tumors (mean±SEM; 2.59±0.19; n=9 mice) 
(Figure 5h). TUNEL staining for cell death revealed no significant change in positive 
nuclei/mm2 in Nckap1f/f tumors (mean±SEM; 41.15±10.08; n=5 mice) vs 49.95±11.67 in 
Nckap1wt/wt tumors (mean±SEM; 49.95±11.67; n=5 mice) (Figure 5i-k). Thus NCKAP1 may 
have a role in regulation of hypoxia due to stromal accumulation and reduced vascularity, 
thereby regulating melanoma growth. 
 











We next asked whether increased collagen deposition and hypoxic signature were associated 
with an inflammatory response. The total number of CD8+ cells/mm2 was significantly 
(P<0.05) increased in Nckap1f/f tumors (mean±SEM; 328.8±33.11; n=7 mice) compared to 
Nckap1wt/wt tumors (mean±SEM; 174.9±39.73; n=7) (Figure 6a-c). Moreover, Nckap1f/f 
tumors showed a significantly (P<0.01) increased number of CD4+ T-cells/mm2 
(mean±SEM; 20.27±3.50, n=7 mice) than Nckap1wt/wt tumors (mean±SEM; 6.95±2.02; n=7 
mice) (Figure S7a-c). The increased T-cell infiltration also correlated with significantly 
(P<0.01) increased CD3+ cell staining in Nckap1f/f tumors (mean±SEM; 24.79±4.28 from 
n=7 Nckap1f/f tumors; 9.71±1.76 from n=7 Nckap1wt/wt tumors) (Figure S7d-f). Next, we 
investigated the presence of mast cells using toluidine staining. The total number of mast 
cells/mm2 was significantly (P<0.01) higher in Nckap1f/f tumors (mean±SEM; 26.73± .31, 
n=7 mice) compared to Nckap1wt/wt tumors (mean ±SEM; 11.07±1.90, n=7 mice) (Figure 6d-
f). There was no significant difference in the total number of F4/80 positive (macrophage) 
cells/mm2 in Nckap1f/f (mean±SEM; 2574±289.7, n=6 mice) compared to Nckap1wt/wt tumors 
(mean±SEM; 2192±450.3; n=6 mice) (Figure 6g-i). We further asked if this increased 
infiltration of immune cells is a result of enhanced cytokine production in the tumors using a 
mouse cytokine array (111 cytokines, Proteome Profile  Mouse XL Cytokine panel, see 
Methods and Figure S8a-b, Table S3). There was no major difference between Nckap1wt/wt 
and Nckap1fl/fl tumors regarding the production of interleukins 2-15 or other pro-inflammatory 
signal mediators detected. A few of the more signifcant changes are highlighted in Figure 
S8c. Altogether, our data suggest that genetic loss of Nckap1 enhances infiltration of anti-












The small GTPase RAC1 is an important driver of cutaneous melanoma (Halaban, 2015)  but 
is not yet druggable. RAC1 drives dermal melanocyte survival and tumor progression and 
metastasis in an NRasQ61K driven genetic model (Li et al., 2012). RAC1 is a m jor upstream 
regulator of NCKAP1; a member of the SCAR/WAVE complex and is frequently mutated to 
an activated state (P29S mutation) or overexpressed in human melanomas (Li and Machesky, 
2013). We thus explored the potential role of the WAVE complex subunit NCKAP1, in 
BRAF V600E/ PTEN loss driven melanoma. While NCKAP1 is not app rently amplified or 
altered in melanomas (e.g. cBioportal TCGA data), it is a crucial effector of Rac1 mediating 
actin dynamics and is likely activated by oncogenic signalling in melanomas. Here we show 
that deletion of NCKAP1 in a mouse model of BRAF PTEN loss driven melanoma delayed 
nevus formation and tumor progression significantly. 
 
RAC1 drives cell cycle progression in melanoma and other cancers (Molinie et al., 2019). We 
previously identified a role of RAC1 (in vivo) and the WAVE complex (in cell culture) in the 
migration of melanoblasts (Li et al., 2012), but lit le is known about a possible role for 
WAVE complex or the subunit NCKAP1 in cell cycle prog ession in cancer. Here, we 
implicate NCKAP1 in onset of naevus and melanoma development and cyclin D1 expression 
leading to cell cycle progression. Nuclear pSMAD3 increased in Nckap1 knockout tumours, 
indicating a possible involvement of TGF-β signaling.  NCKAP1 may thus propagate Rac1 
signaling in a positive feedback loop driving cell cycle progression.  RAC1 signaling depends 
on PI3K, which is known to drive nuclear cyclin D1 and cell cycle progression (Bailey et al., 
2017, Lionarons et al., 2019).  Branched actin downstream of WAVE complex is essential for 
cell cycle progression, further supporting the idea that positive feedback between RAC1 and 
its downstream targets could contribute to tumor prgression (Molinie et al., 2019). Another 








growth in the Braf Pten mouse melanoma model (Damsky et al., 2015). Phosphorylation of 
ribosomal S6 protein was reduced in Nckap1f/f in agreement with the previously reported role 
for NCKAP1 in nutrient sensing via integrin and ECM endocytosis (Rainero et al., 2015). 
Thus, NCKAP1 likely promotes melanoma tumor growth through adhesion-mediated 
cyclinD1 expression and nutrient sensing.  
 
Loss of Nckap1 in mutant Braf;Ptenfl/wt tumors induced a highly fibrotic phenotype and 
enhanced nuclear Yap, consistent with increased pSMAD3 in Nckap1 knockout tumours. 
Fibrosis is observed in the rare desmoplastic type of melanoma (DeWane et al., 2019) and 
also in other cutaneous melanoma types during acquisition of resistance to BRAF inhibitors 
and is associated with activation of the Yap/Taz and MRTF transcriptional pathways (Girard 
et al., 2020). BRaf-resistant melanomas can develop a “drug-protective” stroma (Girard et al., 
2020) that activates Yap-dependent growth pathways and protects tumour cells from exposure 
to inhibitors.  YAP can drive tumour differentiation downstream of TGF-β signaling in 
melanomas (Miskolczi et al., 2018).  In the presence of increased stromal collagen and high 
TGF-β, SMAD and YAP-TEAD complexes led to dedifferentiated slow cycling tumors, 
while in the absence of TGF-B YAP-PAX3 signaling drive MITF high differentiated and 
proliferative tumors (Miskolczi et al., 2018). NCKAP1 knockout tumours also displayed 
hallmarks of differentiation such as increased melanin staining (e.g. see Figure 1e, f), but they 
were not proliferative. The mechanism of collagen accumulation in NCKAP1 tumors is not 
clear, but could involve a role of NCKAP1 in MMP secr tion (e.g. Figure S8c) or a feedback 
loop related to enhanced immune cell recruitment. 
 
Nckap1 depleted tumors also showed enhanced infiltration of CD4+, CD8+ and mast cells, 









CD8+ are anti-tumour T-cells. Mast cells have an unclear role in cutaneous melanoma, but 
are generally thought to be tumour suppressive (Mignogna et al., 2017).  Mast cells carry 
granules of inflammatory mediators such as histamine, heparin and cytokines and can 
modulate the activity of macrophages, with some reporting suggesting they could have both 
tumour provoking and opposing roles (Komi and Redegld, 2020). 
 
Cutaneous melanomas with activating BRaf mutations ccur in approximately 50% of 
patients and BRaf/MEK inhibitor combination therapies can give more than a 75% response 
rate, but also a high relapse rate (Rebecca et al., 2020).  Immune therapies, such as anti-PD-1 
and anti CTLA-4 are also useful, but the response rat  is less than 40% (Rebecca et al., 2020).  
Targeting NCKAP1, or a component of the actin machinery downstream of Rac1 would be 
challenging, but might boost the anti-tumour immune response and slow tumour growth. 
Clearly, more studies are needed to determine whether the apparent feedback loop between 
Rac1- Scar/WAVE and cell cycle progression could be broken with inhibitors, to slow tumour 
growth and possibly to enhance immune infiltration (Model, Figure S9). 
 
Materials and Methods 
 
Transgenic mice and genotyping 
 
All experiments were performed according to UK Home Office regulations and in compliance 
with EU Directive 2010/63 and the UK Animals (Scient fic Procedures) Act 1986 and were 
previously approved by the Animal Welfare and Ethical Review Body (AWERB) of the 









to the corresponding author (PE494BE48). Nckap1f/f mice generation and genotyping are 
described in Supplementary Materials online. 
 
Preparation of tumor lysates  
Tumor samples were weighed and equivalent amount of tumor pieces for each sample were 
lysed in RIPA (50 mM Tris-HCL, 150 mM NaCl, 1% NP-40 v/v and 0.25% w/v Na 
deoxycholate) with Halt protease inhibitor cocktail (Thermofisher A32963) and Halt 
phosphatase inhibitor cocktail (Thermofisher 78428) for 10 min on ice. Tumor samples were 
then homogenized with electronic homogenizer (Precellys24, Stretton Scientific Ltd) and 
clarified at 10,000g using centrifugation (40C). 
 
BrdU incorporation and in vivo proliferation assay 
In vivo proliferation levels of tumors were measured using bromodeoxyuridine (BrdU) 
incorporation assay. Briefly, mice were injected with 250 µl of BrdU (Amersham 
Biosciences, NJ, USA) when the tumors reach endpoint (1.2 cm) and sacrificed after 2 hrs. 
Immunohistochemical staining for BrdU was then performed using an anti-BrdU antibody 




Formalin-fixed paraffin-embedded (FFPE) sections were processed by standard histology 
processing techniques as previously described (Li et al., 2012b).  Details of the antibodies are 












All values expressed as mean ± SEM and statistical analysis was performed using Prism8 
(GraphPad). Unpaired t-test was used to find significance between two groups. The LogRank 
(Mantel cox) test was used to calculate survival distribution between samples. 
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FIGURE 1. Loss of Nckap1 delayed the onset and development of melanoma. 
 
(a-b) Representative images of induced melanoma in Nckap1wt/wt and Nckap1 f/f mice with the 
genetic background Tyr::CreER T2+;Braf V600E+;Ptenwt/f at 56 days (8 weeks) post tamoxifen 
induction. Arrows point to nevi. (c) Number of primary tumors per mouse upon Nckap1 loss 
(n=14 Nckap1wt/wt and n=16 Nckap1 f/f mice) (d) Tumor burden (tumor volume (mm3)) upon 
Nckap1 loss (n=14 Nckap1wt/wt and n=16 Nckap1 f/f mice).  (e-f) Representative images from 
Haematoxylin & Eosin (H&E) staining of tumors from Nckap1wt/wt and Nckap1 f/f mice. Scale 
bars are 500 µm. All error bars show Mean ± SEM. Tumor size is in mm3. Unpaired t-test. 
** P <0.01: **** P<0.0001.  
 
FIGURE 2. Nckap1 is important for cell cycle progression and tumor growth. 
 
(a) Quantification of percentage of BrdU positive nuclei/cells from Nckap1wt/wt (n=5 mice) 
and Nckap1 f/f (n=5 mice) endpoint tumors under the genetic background Tyr::CreER T2+;Braf 
V600E+;Ptenwt/f and after a 2hrs BrdU pulse. (b) Representative images from BrdU staining. (c) 
Quantification of percentage of ki67 positive nuclei/ lls from Nckap1wt/wt (n=5) and Nckap1 
f/f (n=7) tumors from separate mice. (d) Representative images of ki67 staining. (e) 
Quantification of cyclinD1 positive nuclei/cells from Nckap1wt/wt (n=8) and Nckap1 f/f (n=8) 
tumors from separate mice. (f) Representative images of cyclinD1 staining. (g) Tumor growth 









Tumor size is in mm3. Unpaired t-test. *P<0.05: **P <0.01: ***P<0.001:**** P<0.0001:ns = 
not-significant. Scale bars are 100 µm.  
 
FIGURE 3. Nckap1 is dispensable for dermal expansion but essential for melanoma 
progression. 
 
(a) Days to naevus formation from Nckap1wt/wt (n=15 mice) and Nckap1 f/f (n=14 mice) (b) 
tumor formation in Nckap1wt/wt (n=15 mice) and Nckap1 f/f (n= 11 mice) skin post-tamoxifen 
induction under the genetic background Tyr::CreER T2+;Braf V600E+;Ptenwt/f. 
(c-d) H&E staining showing pigmented lesions from Nckap1wt/wt and Nckap1 f/f end-point 
skin. Arrows – dermal lesions. (e) Quantification of pigmented dermis lesions from 
Nckap1wt/wt (n=8 mice) and Nckap1 f/f (n=6 mice) end-point skins post-tamoxifen induction. 
(f) Kaplan-Meier survival curve of mice with the indicated genotypes, Nckap1wt/wt (n=16 
mice), Nckap1f/wt (n=12 mice) and Nckap1 f/f (n=21 mice) under the genetic background of the 
Tyr::CreER T2+;Braf V600E+;Ptenwt/f following local administration of tamoxifen. Log-Rank 
(Mantel-Cox) test of survival plot revealed a significant difference (p<0.0001) between 
Nckap1wt/wt and Nckap1f/f genotypes. All error bars show Mean ± SEM. Unpaired t-test. 
*P<0.05; **P <0.01; ***P<0.001. Scale bars are 200 µm.  
 
FIGURE 4. Nckap1 loss promotes fibrosis in melanomas. 
 
Representative images of Picro Sirius Red staining from Nckap1wt/wt (a) and Nckap1 f/f (b) 
end-point tumor sections under the genetic background of Tyr::CreER T2+;Braf V600E+;Ptenwt/f. 
(c) Quantification of percentage Picro Sirius Red positive area/mm2 from Nckap1wt/wt (n=7) 








collagen structure (correlation) (d) and abundance (homogeneity) (e). Values are average 
intensity± SEM (y-axis) as a function of distance (µm, x-axis) from tumor sections of 
Nckap1wt/wt (n=11) and Nckap1 f/f (n=11) mice quantified using two-photon microscopy. (f) 
Percentage of a-SMA positive area/mm2 in Nckap1wt/wt (n=8) and Nckap1 f/f (n=8) tumors 
from separate mice. All error bars show Mean ± SEM. Unpaired t-test. ns = not-significant. 
Scale bars are 100 µm. 
 
FIGURE 5. Increased expression of HIF1α and reduced vascularization upon Nckap1 
loss. 
 
Serial sections of Nckap1wt/wt stained for (a) S100, (b) HIF1α and (c) CD31. Inset shows 
magnification of area pointed by an arrow. (d-f) Nckap1 f/f serial sections showing (d) S100, 
Tumor cells indicated by asterisk (e) HIF1α and (f) CD31. Nckap1wt/wt and Nckap1 f/f mice are 
under the genetic background of Tyr::CreER T2+;Braf V600E+;Ptenwt/f. (g) Quantification 
showing percentage of HIF1α positive areas/mm2 from Nckap1wt/wt (n=7) and Nckap1 f/f (n=7) 
tumors from separate mice. (h) Quantification of CD31 positive areas/mm2 from Nckap1wt/wt 
(n=9) and Nckap1 f/f (n=9) tumors from separate mice. (i-j) Representative images of TUNEL 
(cell death) staining in Nckap1wt/wt and Nckap1 f/f mice. Insets show magnification. (k) 
Quantification of TUNEL positive nuclei/mm2 from Nckap1wt/wt (n=5) and Nckap1 f/f (n=5) 
endpoint tumors from separate mice. All error bars show mean ± SEM. Unpaired t-test. **P 
<0.01; ***P<0.001; ns = not-significant. Scale bars are 100µm. 
 










(a-b) Representative images from anti-CD8 (T-cells) staining from Nckap1wt/wt and Nckap1 f/f 
tumors under the genetic background of Tyr::CreER T2+;Braf V600E+;Ptenwt/f. (c) 
Quantification of CD8 positive cells/mm2 of Nckap1wt/wt (n=7) and Nckap1 f/f (n=7) tumors 
from separate mice. (d-e) Representative images of toluidine blue (mast cells) staining from 
Nckap1wt/wt and Nckap1 f/f tumors. (f) Quantification of toluidine blue positive cells/mm2 from 
Nckap1wt/wt (n=7) and Nckap1 f/f (n=7) tumors from separate mice. (g-h) Representative 
images of of F4/80 positive cells (macrophages) staining from Nckap1wt/wt and Nckap1 f/f 
tumors from separate mice. (i) Quantification of F4/80 positive cells/mm2 from Nckap1wt/wt 
(n=6) and Nckap1 f/f (n=6) tumors from separate mice. All error bars show mean ± SEM. 
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Table S3 Cytokine array 
Proteome profier Mouse XL Cytokine Array (ARY028) coordinates 
Coordinate Analyte/Control Entrez Gene ID Alternate Nomenclature 
A1, A2 Reference Spots N/A _____ 
A3, A4 Adiponectin/Acrp30 11450 AdipoQ 
A5, A6 Amphiregulin 11839 AR, SDGF 
A7, A8 Angiopoietin-1 11600 Ang-1, Angpt1 
A9, A10 Angiopoietin-2 11601 Ang-2, Angpt2 
A11, A12 Angiopoietin-like 3 30924 ANGPT-L3 
A13, A14 BAFF/BLyS/TNFSF13B 24099 CD257, TALL1, THANK, ZTNF4 
A15, A16 C1q R1/CD93 17064 AA4 Antigen, C1q Rp, CD93 
A17, A18 CCL2/JE/MCP-1 20296 MCAF 
A19, A20 CCL3/CCL4/MIP-1α/β 20302/20303 _____ 
A21, A22 CCL5/RANTES 20304 SISd 
A23, A24 Reference Spots N/A _____ 
B3, B4 CCL6/C10 20305 MRP-1 
B5, B6 CCL11/Eotaxin 20292 _____ 
B7, B8 CCL12/MCP-5 20293 _____ 
B9, B10 CCL17/TARC 20295 _____ 
B11, B12 CCL19/MIP-3β 24047 ELC 
B13, B14 CCL20/MIP-3α 20297 exodus-1, LARC 
B15, B16 CCL21/6Ckine 18829 exodus-2, SCYA21, SLC, TCA-4 
B17, B18 CCL22/MDC 20299 ABCD-1, MDC, STCP-1 
B19, B20 CD14 12475 _____ 
B21, B22 CD40/TNFRSF5 21939 _____ 
C3, C4 CD160 54215 Natural killer cell receptor BY55, NK1; NK28 
C5, C6 Chemerin 71660 RARRES2, TIG-2 
C7, C8 Chitinase 3-like 1 12654 CHI3L1, Cgp39, YKL40 
C9, C10 Coagulation Factor III/Tissue Factor 14066 TF, CD142, Thromboplastin 
C11, C12 Complement Component C5/C5a 15139 C5/C5a 
C13, C14 Complement Factor D 11537 Adipsin, C3 convertase activator, Properdin factor D 
C15, C16 C-Reactive Protein/CRP 12944 _____ 
C17, C18 CX3CL1/Fractalkine 20312 FKN, Neurotactin 
C19, C20 CXCL1/KC 14825 CINC-1; GRO alpha; KC; MGSA-alpha 
C21, C22 CXCL2/MIP-2 20310 GROβ, GRO2, CINC-3 
D1, D2 CXCL9/MIG 17329 CRG-10, CMK 
D3, D4 CXCL10/IP-10 15945 CRG-2, C7 
D5, D6 CXCL11/I-TAC 56066 H174, SCYB9B 
D7, D8 CXCL13/BLC/BCA-1 55985 _____ 
D9, D10 CXCL16 66102 SRPSOX 
D11, D12 Cystatin C 13010 ARMD11, CST3, Gamma-trace 
D13, D14 DKK-1 13380 Dickkopf-1 
D15, D16 DPPIV/CD26 13482 Dpp4, Dipeptidyl-peptidase IV 
D17, D18 EGF 13645 Epidermal Growth Factor 
D19, D20 Endoglin/CD105 13805 ENG 
D21, D22 Endostatin 12822 Col18a1 
D23, D24 Fetuin A/AHSG 11625 AHSG, alpha-2-HS-glycoprotein 
E1, E2 FGF acidic 14164 FGF-1 
E3, E4 FGF-21 56636 _____ 
E5, E6 Flt-3 Ligand 14256 Flt3lg 
E7, E8 Gas 6 14456 Growth Arrest Specific 
E9, E10 G-CSF 12985 Csf3 








E13, E14 GM-CSF 12981 Csf2 
E15, E16 HGF 15234 Scatter Factor, SF, Hepatopoietin-A 
E17, E18 ICAM-1/CD54 15894 _____ 
E19, E20 IFN-γ 15978 IFNG 
E21, E22 IGFBP-1 16006 _____ 
E23, E24 IGFBP-2 16008 _____ 
F1, F2 IGFBP-3 16009 _____ 
F3, F4 IGFBP-5 16011 _____ 
F5, F6 IGFBP-6 16012 _____ 
F7, F8 IL-1α/IL-1F1 16175 _____ 
F9, F10 IL-1β/IL-1F2 16176 _____ 
F11, F12 IL-1ra/IL-1F3 16181 IL1RN 
F13, F14 IL-2 16183 _____ 
F15, F16 IL-3 16187 _____ 
F17, F18 IL-4 16189 B cell-stimulatory factor-1 
F19, F20 IL-5 16191 _____ 
F21, F22 IL-6 16193 _____ 
F23, F24 IL-7 16196 _____ 
G1, G2 IL-10 16153 CSIF 
G3, G4 IL-11 16156 _____ 
G5, G6 IL-12 p40 16160 _____ 
G7, G8 IL-13 16163 _____ 
G9, G10 IL-15 16168 _____ 
G11, G12 IL-17A 16171 _____ 
G13, G14 IL-22 50929 IL-TIF 
G15, G16 IL-23 83430 _____ 
G17, G18 IL-27 p28 246779 _____ 
G19, G20 IL-28A/B 330496/338374 _____ 
G21, G22 IL-33 77125 NF HEV, DVS 27 
G23, G24 LDL R 16835 low density lipoprotein receptor 
H1, H2 Leptin 16846 OB 
H3, H4 LIF 16878 _____ 
H5, H6 Lipocalin-2/NGAL 16819 Siderocalin, 24p3 
H7, H8 LIX 20311 CXCL5, GCP-2, ENA-78 
H9, H10 M-CSF 12977 CSF-1 
H11, H12 MMP-2 17390 Gelatinase A 
H13, H14 MMP-3 17392 Stromelysin-1 
H15, H16 MMP-9 17395 Clg4b, Gelatinase B, GELB 
H17, H18 Myeloperoxidase 17523 MPO 
H19, H20 Osteopontin (OPN) 20750 Eta-1, Spp1 
H21, H22 Osteoprotegerin/TNFRSF11B 18383 OPG, Ocif 
H23, H24 PD-ECGF/Thymidine phosphorylase 72962 dThdPase, ECGF1, Gliostatin, MEDPS1, MNGIE 
I1, I2 PDGF-BB 18591 _____ 
I3, I4 Pentraxin 2/SAP 20219 PTX2 
I5, I6 Pentraxin 3/TSG-14 19288 PTX3 
I7, I8 Periostin/OSF-2 50706 Fasciclin I-like, POSTN, TRIF52 
I9, I10 Pref-1/DLK-1/FA1 13386 DLK1, pG2, ZOG 
I11, I12 Proliferin 18811 MRP 
I13, I14 Proprotein Convertase 9/PCSK9 100102 NARC-1 
I15, I16 RAGE 11596 AGER 
I17, I18 RBP4 19662 Retinol-Binding Protein 4 
I19, I20 Reg3G 19695 PAP3 








J1, J2 Reference Spots N/A _____ 
J3, J4 E-Selectin/CD62E 20339 ELAM1, LECAM2, Sele 
J5, J6 P-Selectin/CD62P 20344 GMP-140, LECAM3, Selep 
J7, J8 Serpin E1/PAI-1 18787 Nexin, PLANH1 
J9, J10 Serpin F1/PEDF 20317 EPC-1 
J11, J12 Thrombopoietin 21832 Tpo, MGDF 
J13, J14 TIM-1/KIM-1/HAVCR 171283 _____ 
J15, J16 TNF-α 21926 TNFSF1A 
J17, J18 VCAM-1/CD106 22329 _____ 
J19, J20 VEGF 22339 VEGF-A, VPF 
J21, J22 WISP-1/CCN4 22402 _____ 















        
               Name Genotype No of Primary Tumor Date of Birth Sex Coat Date of Inductio Date of First Ne Date of First Tu mDate of Death Survival Naevus Tumor Free Naevus to Tumor Comments 
203594 Tyr::CreERT2+; BrafV600E+; Pten wt/f; Nckap1  wt/wt 4 12/01/2015 Female N/A 11/05/2015 26/06/2015 03/07/2015 12/08/2015 93 46 53 7 Culled by Schedule1 - took inguinal LNs, Liver, Tumor samples for Histology. LNs positive for   melanoma. 
BKSE3.1b Tyr::CreERT2+; BrafV600E+; Pten wt/f; Nckap1  wt/wt 5 30/03/2015 Male Black 01/06/2015 03/07/2015 23/07/2015 26/08/2015 86 32 52 20 Culled-Tumor Bleeding-Tumors, LNs, and Organs taken for Histology-GOT Histology   Back 
BKSE2.1b Tyr::CreERT2+; BrafV600E+; Pten wt/f; Nckap1  wt/wt 6 30/03/2015 Female Black 01/06/2015 15/07/2015 06/08/2015 29/09/2015 120 44 66 22 Induced 01/06/2015 Culled Samples for histology 
BKSE10.1A Tyr::CreERT2+; BrafV600E+; Pten wt/f; Nckap1  wt/wt 10 18/08/2015 Male Black 12/10/2015 01/12/2015 14/12/2015 18/01/2016 98 50 63 13 Induced 12/10/2015 reached endpoint..Brdu-ed..LNs positive..tumor and organs for histology. 
BKSE10.1C Tyr::CreERT2+; BrafV600E+; Pten wt/f; Nckap1  wt/wt 10 18/08/2015 Male Black 12/10/2015 24/11/2015 01/12/2015 31/12/2015 80 43 50 7 Reached Endpoint. Brdu.LNs positive..Organs and Primary Tumor for Histology 
BKSE10.1E Tyr::CreERT2+; BrafV600E+; Pten wt/f; Nckap1  wt/wt 7 18/08/2015 Female Black 12/10/2015 11/12/2015 22/12/2015 08/01/2016 88 60 71 11 Induced 12/10/2015 Ulcerated Tumor..Brdu-ed..LNs positive.Organs for Histology 
BKSE10.1F Tyr::CreERT2+; BrafV600E+; Pten wt/f; Nckap1  wt/wt 6 18/08/2015 Female Black 12/10/2015 01/12/2015 11/12/2015 08/01/2016 88 50 60 10 Induced 12/10/2015 Ulcerated Tumor..Brdu-ed..LNs positive.Organs for Histology 
BKSE9.2a Tyr::CreERT2+; BrafV600E+; Pten wt/f; Nckap1  wt/wt 11 16/08/2015 Female Black 12/10/2015 24/11/2015 01/12/2015 05/01/2016 85 43 50 7 Induced 12/10/2015 Reached endpoint.Brdu-ed LNs positive Organs for Histology 
BKSE10.2d Tyr::CreERT2+; BrafV600E+; Pten wt/f; Nckap1  wt/wt 3 09/09/2015 Female Black 09/11/2015 18/12/2015 22/12/2015 13/01/2016 65 39 43 4 Induced 09/11/2015 Reached endpoint..LNs positive..Tumor fragment into nude mice for cell line..tumor and organs for   histology. 
BKSE10.2e Tyr::CreERT2+; BrafV600E+; Pten wt/f; Nckap1  wt/wt 9 09/09/2015 Female Black 09/11/2015 22/12/2015 26/12/2015 18/01/2016 70 43 47 4 Induced 09/11/2015 necrotic tumor..Brdu-ed..LNs positive..primary tumor and organs for histology. 
BKSE10.3a Tyr::CreERT2+; BrafV600E+; Pten wt/f; Nckap1  wt/wt 
 
01/10/2015 Male Black 23/11/2015 31/12/2015 05/01/2016 22/01/2016 60 38 43 5 Induced 23/11/2015 Reached endpoint..one eye is replaced by a tumor..concern raised by Evarest..Brdu-ed..LNs positive..Tumor and organs for histology. 
BKSE10.3b Tyr::CreERT2+; BrafV600E+; Pten wt/f; Nckap1  wt/wt 
 
01/10/2015 Male Black 23/11/2015 14/01/2016 26/01/2016 05/02/2016 74 52 64 12 Induced 23/11/2015 Reached endpoint..Brdu-ed..LNs positive..tumor and organs for histology 
BKSE10.3c Tyr::CreERT2+; BrafV600E+; Pten wt/f; Nckap1  wt/wt 1 01/10/2015 Female Black 23/11/2015 18/12/2015 22/12/2015 07/01/2016 45 25 29 4 Induced 23/11/2015 Bleeding Tumor..Brdu-ed..LNs positive.Organs for  Histology 
BKSE10.3e Tyr::CreERT2+; BrafV600E+; Pten wt/f; Nckap1  wt/wt 9 01/10/2015 Female Black 23/11/2015 22/12/2015 26/12/2015 15/01/2016 53 29 33 4 Induced 23/11/2015 Necrotic Tumor..Close to endpoint..Brdu-ed..LNs positive..Tumor and Organs for Histology 
BKSE10.4b Tyr::CreERT2+; BrafV600E+; Pten wt/f; Nckap1  wt/wt 
 
26/11/2015 Female Black 18/01/2016 22/03/2016 22/03/2016 12/04/2016 85 64 64 0 Induced 18/01/2016 Reached endpoint..Sample and skin taken for histology with RNAscope processing..taken RNA, ear and skin   sample.. 
BKSE10.4c Tyr::CreERT2+; BrafV600E+; Pten wt/f; Nckap1  wt/wt 
 
26/11/2015 Female Black 18/01/2016 nd nd 11/04/2016 84 nd nd nd Induced 18/01/2016 Reached Endpoint..Brdu-ed..Samples taken for histology..skin sample taken as  wel.. 
BKSE21.1b Tyr::CreERT2+; BrafV600E+; Pten wt/f; Nckap1  wt/wt 
 
17/02/2017 Male Agouti 26/05/2017 nd nd 10/07/2017 45 nd nd nd Induced 26/05/2017 - Taken down 6W cohorts. Reached endpoint merged tumors. Tumor for RNA, protein and histology. Skin for histology and frozen   sections 
               
               Name Genotype No of Primary Tumor Date of Birth Sex Coat Date of Inductio Date of First Ne Date of First Tu mDate of Death Survival Naevus Tumor Free Naevus to Tumor Comments 
BKSE1.1d Tyr::CreERT2+; BrafV600E+; Pten wt/f; Nckap1  wt/f 
 
27/03/2015 Male Black 01/06/2015 03/07/2015 23/07/2015 04/09/2015 95 32 52 20 Tumor Reached endpoint - Taken samples for Histology and cell line establishment-GOT    BACK HISTOLOGY 
BKSE1.1f Tyr::CreERT2+; BrafV600E+; Pten wt/f; Nckap1  wt/f 
 
27/03/2015 Male Black 01/06/2015 03/07/2015 23/07/2015 25/08/2015 85 32 52 20 Reached Endpoint-Culled-Tumor, Organs, LNs taken for Histology. Tumor also taken for cell line establishment.-GOT    BACK Histology 
BKSE1.5a Tyr::CreERT2+; BrafV600E+; Pten wt/f; Nckap1  wt/f 
 
24/06/2015 Female Black 10/08/2015 23/09/2015 30/10/2015 08/12/2015 120 44 81 37 Culled as the tumor reached endpoint. Brdu injected..Met in LNs..Organs for histology.. 
BKSE5.2a Tyr::CreERT2+; BrafV600E+; Pten wt/f; Nckap1  wt/f 
 
30/06/2015 Female Black 24/08/2015 06/10/2015 06/11/2015 05/01/2016 134 43 74 31 Necrotic Tumor..Brdu-ed LNs postive Organs for Histology 
BKSE8.1f Tyr::CreERT2+; BrafV600E+; Pten wt/f; Nckap1  wt/f 
 
02/07/2015 Female Black 24/08/2015 03/11/2015 06/11/2015 15/12/2015 113 71 74 3 Reached Endpoint..Brdu-ed..LNs positive..Organs for Histology 
BKSE8.3d Tyr::CreERT2+; BrafV600E+; Pten wt/f; Nckap1  wt/f 
 
01/09/2015 Female Black 12/10/2015 14/12/2015 26/12/2015 17/02/2016 128 63 75 12 Brdu-ed..LNs positive..Tumor and Organs for histology 
BKSE6.6e Tyr::CreERT2+; BrafV600E+; Pten wt/f; Nckap1  wt/f 
 
26/10/2015 Female Black 18/01/2016 nd nd 08/06/2016 142 nd nd nd Reached endpoint..Tumor, LNs, ORG, and Skin for histology..Tum for  RNA 
BKSE16.1b Tyr::CreERT2+; BrafV600E+; Pten wt/f; Nckap1  wt/f 
 
03-Jul-16 Male Black 26/09/2016 nd nd 13/12/2016 78 nd nd nd tumor reached endpoint - sampled for histology 
BKSE17.3a Tyr::CreERT2+; BrafV600E+; Pten wt/f; Nckap1  wt/f 
 
17/11/2016 Female Black 03/02/2017 nd nd 03/04/2017 59 nd nd nd For RNAsseq -Tumor sample at  endpoint 
BKSE22.2a Tyr::CreERT2+; BrafV600E+; Pten wt/f; Nckap1  wt/f 
 
14/03/2017 Male Black 26/05/2017 nd nd 01/08/2017 67 nd nd nd Reached endpoint. Sampled for histology. 
BKSE22.2b Tyr::CreERT2+; BrafV600E+; Pten wt/f; Nckap1  wt/f 
 
14/03/2017 Male Black 26/05/2017 nd nd 28/07/2017 63 nd nd nd Reached Endpoint. Tumor for histology and protein. LNs for histology. 
BKSE22.2c Tyr::CreERT2+; BrafV600E+; Pten wt/f; Nckap1  wt/f 
 
14/03/2017 Male Agouti 26/05/2017 nd nd 20/07/2017 55 nd nd nd Reached endpoint. tumor near mouth and also in belly. showed enlarged scrotum. Tumor for RNA, protein and histology. skin for frozen and   histology. 
BKSE21.1f Tyr::CreERT2+; BrafV600E+; Pten wt/f; Nckap1  wt/f 
 
17/02/2017 Male Agouti 26/05/2017 nd nd 28/07/2017 63 nd nd nd Reached endpoint. tumor for histology and RNA. Tumor also sampled for cell line   establishment 
               
               Name Genotype No of Primary Tumor Date of Birth Sex Coat Date of Inductio Date of First Ne Date of First Tu mDate of Death Survival Naevus Tumor Free Naevus to Tumor Comments 
BKSE3.1f Tyr::CreERT2+; BrafV600E+; Pten wt/f; Nckap1  f/f 2 30/03/2015 Female Black 01/06/2015 30/07/2015 20/08/2015 22/10/2015 143 59 80 21 Culled as the primary tumor was slightly bleeding- Samples taken for Histology and cell    line establishment. 
BKSE7.1b Tyr::CreERT2+; BrafV600E+; Pten wt/f; Nckap1  f/f 4 06/06/2015 Male Black 10/08/2015 23/09/2015 30/10/2015 07/01/2016 150 44 81 37 Tumor necrotic..Brdued.LN positive.organs for histology. 
BKSE5.1d Tyr::CreERT2+; BrafV600E+; Pten wt/f; Nckap1  f/f 3 11/06/2015 Male Black 10/08/2015 06/10/2015 30/10/2015 08/01/2016 151 57 81 24 Reached Endpoint..Brdu-ed LNs positive..Organs for Histology 
BKSE4.3a Tyr::CreERT2+; BrafV600E+; Pten wt/f; Nckap1  f/f 1 18/06/2015 Male Black 10/08/2015 nd 20/10/2015 14/12/2015 126 nd 71 nd Tumor reached endpoint and bleeding..Brdu injected..samples taken for histology..LNs positive 
BKSE5.2b Tyr::CreERT2+; BrafV600E+; Pten wt/f; Nckap1  f/f 1 30/06/2015 Female Black 24/08/2015 03/11/2015 11/01/2016 03/02/2016 163 71 140 69 Mice had a fatty cystic mass in its head..so has to be taken down before endpoint..LNs are positive..send for   histology 
BKSE5.3b Tyr::CreERT2+; BrafV600E+; Pten wt/f; Nckap1  f/f 1 27/07/2015 Female Black 12/10/2015 nd 11/12/2015 27/12/2015 76 nd 60 nd Reached Endpoint LNs positive Organs and Primary Tumor for  Histology 
BKSE5.3d Tyr::CreERT2+; BrafV600E+; Pten wt/f; Nckap1  f/f 1 27/07/2015 Female Black 12/10/2015 22/12/2015 23/02/2016 01/04/2016 172 71 134 63 Tumor reached endpoint..Brdu-ed..Tum and organs for histology..skin sample for histology as  well. 
BKSE6.3e Tyr::CreERT2+; BrafV600E+; Pten wt/f; Nckap1  f/f 1 15/08/2015 Female Black 12/10/2015 nd 26/12/2015 05/02/2016 116 nd 75 nd Reached Endpoint Brdu-ed..LNs positive..Tumor and organs for histology 
BKSE7.3d Tyr::CreERT2+; BrafV600E+; Pten wt/f; Nckap1  f/f 1 29/08/2015 Female Black 12/10/2015 08/12/2015 07/01/2016 23/02/2016 134 57 87 30 Tumor near mouth..reached endpoint..Brdu-ed..LNs positive..Primary tumors and organs for histology.. 
BKSE5.4a Tyr::CreERT2+; BrafV600E+; Pten wt/f; Nckap1  f/f 1 24/08/2015 Male Black 12/10/2015 14/12/2015 nd 23/02/2016 134 63 nd nd Tumor underside.reached endpoint...very flat spongy tumor..Brdu-ed..LNs positive..Primary tumor and organs for histology. 
BKSE5.4c Tyr::CreERT2+; BrafV600E+; Pten wt/f; Nckap1  f/f 1 24/08/2015 Male Black 12/10/2015 21/11/2015 01/12/2015 13/01/2016 93 40 50 10 tumor fragment into nude mice for cell line..LNs positive..tumor and organs for   histology.. 
BKSE5.4e Tyr::CreERT2+; BrafV600E+; Pten wt/f; Nckap1  f/f 1 24/08/2015 Female Black 12/10/2015 11/12/2015 nd 29/05/2016 230 60 nd nd Necrotic tumor.LN positive.Tumor near scruff..Lungs looked positive..more tumors in ear..RNA, protein, Skin, ear sampled..only  histology 
BKSE5.4f Tyr::CreERT2+; BrafV600E+; Pten wt/f; Nckap1  f/f 1 24/08/2015 Female Black 12/10/2015 31/12/2015 nd 29/05/2016 230 80 nd nd no primary tumor..tumors in ear..skin, LNs, organs for histology.. 
BKSE11.1d Tyr::CreERT2+; BrafV600E+; Pten wt/f; Nckap1  f/f 3 28/08/2015 Female Black 12/10/2015 nd 01/12/2015 25/02/2016 136 nd 50 nd Reached endpoint..Brdu-ed..LNs positive..Tumors and organs and Skin for Histology..sampled for  RNA 
BKSE11.1e Tyr::CreERT2+; BrafV600E+; Pten wt/f; Nckap1  f/f 4 28/08/2015 Female Black 12/10/2015 31/12/2015 14/01/2016 05/04/2016 176 80 94 14 Reached Endpoint..Brdu-ed Primary tumor, skin, and organs for histology..Ear sample and RNA sample  taken.. 
BKSE11.1f Tyr::CreERT2+; BrafV600E+; Pten wt/f; Nckap1  f/f 1 28/08/2015 Female Black 12/10/2015 nd 22/12/2015 15/02/2016 126 nd 71 nd Reached Endpoint..Brdu-ed Primary tumor, skin, and organs for histology..Ear sample and RNA sample  taken.. 
BKSE5.5d Tyr::CreERT2+; BrafV600E+; Pten wt/f; Nckap1  f/f 4 17/09/2015 Male Black 09/11/2015 nd 26/12/2015 29/01/2016 81 nd 47 nd Tumor reached endpoint..LNs positive..Brdu-ed..Primary tumor and organs for histology 
BKSE12.1e Tyr::CreERT2+; BrafV600E+; Pten wt/f; Nckap1  f/f 1 17/09/2015 Female Black 09/11/2015 08/01/2016 14/01/2016 18/03/2016 130 60 66 6 Reached endpoint..Primary tumor and organs for histology..Skin for histology..asked ki67..have taken ear and RNA  sample 
BKSE12.1g Tyr::CreERT2+; BrafV600E+; Pten wt/f; Nckap1  f/f 1 17/09/2015 Female Black 09/11/2015 31/12/2015 26/01/2016 26/02/2016 109 52 78 26 Reached endpoint..LNs positive..Tumors and Organs and Skin for histology..RNA sample  taken. 
BKSE6.4c Tyr::CreERT2+; BrafV600E+; Pten wt/f; Nckap1  f/f 2 10/09/2015 Female Black 09/11/2015 nd 09/08/2016 13/09/2016 309 nd 274 nd necrotic tumor..reached endpoint..LNs positive..Lungs and organs negative..Tum for RNA and protein..skin for histology..ear histology and stored.. 
BKSE6.6h Tyr::CreERT2+; BrafV600E+; Pten wt/f; Nckap1  f/f 1 26/10/2015 Female Black 18/01/2016 22/02/2016 05/04/2016 19/07/2016 183 35 78 43 
 








Table S2 Tumour Growth Data 
 BKSE3.1f BKSE4.3a BKSE6.3e BKSE5.4c BKSE11.1a BKSE11.1f BKSE12.1e 
 Raw Values Raw Values Raw Values Raw Values Raw Values Raw Values Raw Values 
Day1 May be 2.7x2.7 2.8x2.8 3.4x3.4 3.3x3.3 1.8x1.8 1.6x1.6 2(1x1) 
Day7 4.3x4.3 4.3x4 3.6x3.5 4.5x4.5 2(3.1x3.1) 3x2.9 2.8x2.8 
Day14 5.1x4 5.3x4.9 5.6x5.4 5.4x4.9 4.6x3.8 4.7x3.7 3.9x3.6 
Day21 5.9x5.2 5.8x5.2 6.8x6.6  4.3x4.2 5.2x5 4.6x4 
Day28 6.2x5.7 7.3x7.3 8.5x7.8 7.3x7 6.6x4.5 7.2x7.2 5.4x4.5 
Day35 6.3x6.3 7.7x7.5 10x10 8.1x7.6 7.9x6.6 9.1x8.9 6.7x6.2 
Day42 7.6x6.9 9.4x8.1 12.3x11.8 9.5x9.3 8.6x7.3 10x9.3 7x7 
Day49 9.4x8.8 10.8x9.8  9.9x9.3  12x12  
Day56 10.8x10.2 11x10.4      
Day63        
Day70        
Day77        
        
 Tumor Volume Tumor Volume Tumor Volume Tumor Volume Tumor Volume Tumor Volume Tumor Volume 
Day1 9.8415 2.8 19.652 17.9685 2.916 2.048 0.5 
Day7 39.7535 4 22.05 45.5625 14.8955 12.615 10.976 
Day14 40.8 63.6265 81.648 64.827 33.212 32.1715 25.272 
Day21 79.768 78.416 148.104 0 37.926 65 36.8 
Day28 100.719 194.5085 258.57 178.85 66.825 186.624 54.675 
Day35 125.0235 216.5625 500 233.928 172.062 360.4055 128.774 
Day42 180.918 308.367 856.326 410.8275 229.1 432.45 171.5 
Day49 363.968 518.616  428.1255  864  
Day56 561.816 594.88      
Day63        
Day70        
























































































































































































































































































































































































































































































































































































































































































































































































































































































The RAC1 target NCKAP1 plays a crucial role in progression of BRAF/PTEN -driven 
melanoma in mice 
 
Supplementary Figure Legends 
 
FIGURE S1. Nckap1f/f;BrafV600E/+;Ptenwt/f melanoma model schematics. 
(a) Nckap1 targeted allele. Screening oligos F = forward and R1, R2 = reverse, are shown as 
red arrows. (b) Schematics of the melanoma mouse model. (c) PCR showing the presence of 
FLP region in genomic DNA isolated from Nckap1wt/wt and Nckap1f/f endpoint tumors from 
n= 3 separate mice (wt – 294 bp; flp – 395 bp) or H2O no DNA control. (d) PCR showing the 
efficiency of recombination in genomic DNA isolated from Nckap1wt/wt and Nckap1f/f 
endpoint tumors from n=2 separate mice (wt – 1200 bp; CRE-Del – 460 bp). (e) Kaplan-
Meier tumor-free survival curve of mice with the ind cated genotypes, Nckap1wt/wt (n=15 
mice), Nckap1f/wt (n=6 mice) and Nckap1 f/f (n=18 mice) under the genetic background of the 
Tyr::CreER T2+;Braf V600E+;Ptenwt/f following local administration of tamoxifen. Log-Rank 
(Mantel-Cox) test of survival plot revealed a significant difference (p<0.0001) between 
Nckap1wt/wt and Nckap1f/f genotypes. **** P<0.0001.  
 
 
FIGURE S2. pERK staining upon Nckap1 loss in melanoma. 
(a-b) Representative images of pERK (p42/44) staining from Nckap1wt/wt and Nckap1 f/f 
endpoint tumors under the genetic background Tyr::CreER T2+;Braf V600E+;Ptenwt/f. (c) 








Nckap1 f/f (n=6) tumors from separate mice. All error bars show mean ± SEM. Unpaired t-
test. ns = not significant. Scale bar is 100 µm. 
 
FIGURE S3. Increased TGFb signaling upon Nckap1 loss 
(a-d) Representative images of Picro Sirius Red (a-c) and S100 (b-d) staining from 
Nckap1wt/wt and Nckap1 f/f endpoint tumors with the genetic background Tyr::CreER T2+;Braf 
V600E+;Ptenwt/f. Scale bar is 1 mm. (e-f) Representative images of pSMAD3 staining from 
Nckap1wt/wt and Nckap1 f/f endpoint tumors under the genetic background Tyr::CreER 
T2+;Braf V600E+;Ptenwt/f. (g) Quantification of the percentage of pSMAD3 positive nuclei from 
Nckap1wt/wt (n=5) and Nckap1 f/f (n=6) tumors from separate mice. All error bars show mean ± 
SD. Unpaired t-test. *P <0.05. Scale bar is 100 µm. 
 
FIGURE S4. p21 staining upon Nckap1 loss in melanoma. 
(a-b) Representative images of p21 staining from Nckap1wt/wt and Nckap1 f/f endpoint tumors 
with the genetic background Tyr::CreER T2+;Braf V600E+;Ptenwt/f. (c) Quantification of 
percentage of p21 positive nuclei/mm2 from Nckap1wt/wt (n=11) and Nckap1 f/f (n=8) tumors 
from separate mice. All error bars show mean ± SEM. Unpaired t-test. ns = not significant. 
Scale bar is 100 µm. 
 
FIGURE S5. YAP and pSRC staining upon Nckap1 loss in melanoma. 
(a) Representative images of YAP staining from Nckap1wt/wt and (b) Nckap1 f/f endpoint 
tumors with the genetic background Tyr::CreER T2+;Braf V600E+;Ptenwt/f. (c) Quantification of 
percentage of YAP positive cells/mm2 from Nckap1wt/wt (n=6) and Nckap1 f/f (n=6) tumors 
from separate mice. (d) Representative images of pSRC (Tyr416) staining from Nckap1wt/wt 








cells/mm2 from Nckap1wt/wt (n=7) and Nckap1 f/f (n=7) tumors from separate mice. All error 
bars show mean ± SEM. Unpaired t-test. *P<0.05, **P <0.01, ns = not significant. Scale bars 
are 100 µm. 
 
FIGURE S6. Decreased activation of mTOR upon Nckap1 loss in melanoma. 
(a) Representative images of pS6 (Ser235/236) staining from Nckap1wt/wt and (b) Nckap1 f/f 
endpoint tumors with the genetic background Tyr::CreER T2+;Braf V600E+;Ptenwt/f. (c) 
Quantification of percentage of pS6 positive cells/mm2 from Nckap1wt/wt (n=8) and Nckap1 f/f 
(n=8) tumors from separate mice. All error bars show mean ± SEM. Unpaired t-test. *P<0.05. 
Scale bar is 100 µm. 
 
FIGURE S7. CD4 and CD3 staining upon Nckap1 loss in melanoma. 
(a) Representative images of anti-CD4 staining from Nckap1wt/wt and (b) Nckap1 f/f endpoint 
tumors under the genetic background Tyr::CreER T2+;Braf V600E+;Ptenwt/f. (c) Quantification 
of percentage of CD4+ positive T-cells/mm2 from Nckap1wt/wt (n=7) and Nckap1 f/f (n=7) 
tumors. (d) Representative images of CD3+ T-cells staining from Nckap1wt/wt and (e) Nckap1 
f/f endpoint tumors and (f) Quantification of percentage of CD3+ positive T-cells from 
Nckap1wt/wt (n=7) and Nckap1 f/f (n=7) tumors from separate mice. All error bars show mean ± 
SEM. Unpaired t-test. **P <0.01. Scale bar is 100 µM. 
 
FIGURE S8. Cytokine array screen of Nckap1 wt and knockout tumors. 
(a) Representative images of cytokine blot prepared from Nckap1wt/wt and (b) Nckap1 f/f 
endpoint tumor lysates under the genetic background Tyr::CreER T2+;Braf V600E+;Ptenwt/f. (c) 








Nckap1 f/f (n=2) tumors using ImageJ. (d) Image of cytokine array template.  See Table S3 for 
the key to the individual cytokines. 
 
Figure S9. Model for how NCKAP1 loss affects BRAF V600E; PTEN loss melanoma.  The 
left hand side shows melanomas in the BRAF V600E; PTEN loss model, where cyclinD1 
activation mediates cell cycle progression downstream of oncogenic transformation.  Rac1 is 
activated as a part of the oncogenic programme and triggers activation of the Scar/WAVE 
complex, leading to increased production of branched actin via Arp2/3 complex and 
enhanced motility.   Feedback from branched actin sustains high activity of this pathway and 
promotes proliferation and invasion.  The right-hand side shows a summary of some of our 
key findings in NCKAP1 null tumours, where the loop between rac1 and branched actin was 
broken by disabling the Scar/WAVE complex.  Tumours displayed nuclear SMAD3 and 
higher levels of nuclear Yap, but the link with cell cycle progression and proliferation was 
broken by NCKAP1 loss, leading to fibrosis, inflammation and slowing of tumour growth.  
Immune infiltration was also enhanced, possibly dueto increased TGF-β signalling.  We thus 
propose that cytoskeletal dynamics downstream of oncogenic signalling represents an 




Transgenic mice generation and genotyping 
The Nckap1 flox mouse strain was created using a targeting vector (PG00182_Z_4_C05) 
obtained from the EuMMCR (European Mouse Mutant cell R pository) (www.eummcr.org) 
and generated by the IMPC/HMGU consortium for the T European Conditional Mouse 








HM1 mESCs (Magin et al, 1992). Cells were selected with G418 (350 µg/ml) and surviving 
colonies were picked and screened for targeting by long range PCR (using the Roche Expand 
Long Template PCR System) from the lacZ/Neo-resistance cassette to sequences beyond the 
ends of the homology arms. Correct targeting of Nckap1 was confirmed on DNA extracted 
from the ES cell clone by PCR on the 5’ side 
(CAGCAAGACCTGTCATAGATCTTATCCAAC and 
CACAACGGGTTCTTCTGTTAGTCC; 6.5kb) and on the 3’ side 
(TCTATAGTCGCAGTAGGCGG 
and CATGTTGTCCGCGTGACGGAGCAGC; 5.3kb). The presence of the isolated 3’ loxP 
site was also confirmed by PCR (GGGGTTAGAGAGTTGATCATTG and 
GAGACGTACCTGCCTCTGTCC; 398bp). 
Following identification of correctly targeted clones, mouse lines were derived by injection 
of ES cells into C57BL/6J blastocysts according to standard protocols (Nagy et al. 2003). 
After breeding of chimeras, germline offspring were id ntified by coat colour and the 
presence of the modified allele was confirmed with the 3’ loxP primers described above. 
Mice were subsequently crossed with a mouse line expressing Flpe 
(Tg(ACTFLPe)9205Dym) to delete the selectable marker by recombination at the FRT sites 
(Rodriguez et al. 2000). Correct removal of the lacZ gene and Neo cassette was confirmed by 
PCR across the remaining FRT site (TGAGCTTTCACTCCCTACC and; 
GCAACAACCTCCATCACTGG; 566bp). 
 
Primers used for genotyping 
The presence of floxed alleles was confirmed by PCR across the FRT site 
(CTCTCTTGTCTACTGTGCAG and; CAAGAAACTTCGGTGTGATTT; 395bp) and the 








(CTCTCTTGTCTACTGTGCAGG and; CTCGTAGACCAAACTAGCCTCAAG; 460bp). 
See Figure S1a-d.  
 
Generation of transgenic melanoma model 
The Nckap1 floxed mice are in C57BL/6J mixed background and show no phenotype in the 
absence of Cre. Tyrosinase Cre-ERT2 (Tyr::Cre-ERT2) mice were previously described 
(Yajima et al, 2006). The Braf CA (BrafV600E+/0) mice were described in (Dankort et al, 
2007) and PTEN (Ptenf/f) floxed allele was described previously (Dankort et al, 2009). The 
Nckap1 floxed mice were bred with animals under the genetic background Tyr::Cre-
ER+/0;BrafV600E+/0;Ptenwt/f to obtain Tyr::Cre-ER+/0;BRafV600E+/0;Ptenwt/f; Nckap1 wt/wt 
(WT controls) Tyr::Cre-ER+/0;BrafV600E+/0;Ptenwt/f;Nckap1fwtf and Tyr::Cre-
ER+/0;BrafV600E+/0;Ptenwt/f;Nckap1f/f animals. Genotyping of the cohort was performed as 
described previously (Yajima et al., 2006, Dankort et al, 2007, Dankort et al, 2009) and by 
the company Transnetyx Inc (Memphis, TN, USA). 
 
Transgene induction and animal monitoring 
Mice were induced by application of 200 µl of 2 mg/mL Tamoxifen (SIGMA – T5648) on 
the back skin of the animals after shaving. The induction regime was continued for five 
consecutive days. Animals were closely monitored for the formation of visible naevus (black 
spots) on the back skin and the date is logged. Tumors were measured three times a week and 
animals were sacrificed at endpoint (tumor size 1.2 cm diameter). Tumor volume was 












Protein concentrations from tumor lysates were measur d using Precision Red Advanced 
Protein Kit (Cytoskeleton, Inc). The Cytokine Array (Proteome Profiler Mouse XL Cytokine 
Array ARY028, R&D systems) was incubated overnight (40C) with equivalent amount of 
protein lysates from different genotypes and the membrane was processed according to 
manufacturer’s instructions. The pixel intensity of the Cytokine spots was calculated 
according to the manufacturer’s instructions using Image J and relative intensity values were 





Formalin-fixed paraffin-embedded (FFPE) sections were processed by standard histology 
processing techniques as previously described (Li et al., 2012b). The following antibodies 
were used: BrdU (BD biosciences 347580, pH6 1:200), CD3 (AbCam ab16669, pH6 1:50), 
CD4 (eBioscience 14-9766-82, ER2 Leica, 1:500), CD8 (eBioscience 14-0808-82, ER2 
Leica,1:500), S100A9 (Santa Cruz sc-8115, pH6 1:1000), pSMAD3 (Abcam ab52903, pH6, 
1:40), aSMA (Sigma-Aldrich A2547, pH6, 1:25000), CD31 (Abcam ab28364, pH6, 1:75), 
ki67 (Abcam ab16667, pH6, 1:100), F4-80 (Abcam ab6640, Enz 1 Leica, 1:100), pERK1/2 
(Cell Signalling 9101, pH6, 1:400), HIF1a (BD biosciences 610959, pH6, 1:50), YAP (Cell 
Signalling 4912, pH6, 1:50), and cyclinD1 (Abcam ab134175, pH6, 1:200). All primary 
antibody incubations were performed for 40 minutes except for cyclinD1 which is for 2hrs. 
Picro Sirius Red staining was used to stain for collagen and fibrin in the tissues. Briefly, 
sections were rehydrated and immersed for 2hrs in Picro Sirius Red solution (0.1% Direct red 








cells, toluidine blue staining was used. Briefly, rehydrated sections were immersed for 5 
minutes in toluidine blue solution (0.1% toluidine blue in 1% Nacl solution). Slides were 
dehydrated using standard protocols post staining and mounted for analysis. Images were 
taken using Olympus BX51 microscope and/or slides wre scanned using Leica SCN 400f 
scanner. The scanned images were processed and analysed using HALO Image Analysis 
Software (Indica Labs). 
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